Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06445959
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-05-31
Brief Title:
Phase 1b2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Mutant IDH1 Inhibitor Olutasidenib |
Keywords: